vTv Therapeutics Reports $1.0 Million Revenue and $18.5 Million Net Loss for Fiscal Year 2024

vTv Therapeutics Inc. reported its financial results for the fiscal year ending December 31, 2024, revealing a modest revenue of $1.0 million, a significant increase from no revenue in the previous year. This revenue was primarily attributed to a milestone payment from the Newsoara License Agreement. Despite this uptick in revenue, the company continues to face substantial operating losses, reporting a net loss of $18.5 million for 2024, a slight improvement from the $20.3 million loss in 2023. The accumulated deficit now stands at approximately $299.7 million.

The company’s research and development expenses decreased to $11.5 million in 2024 from $13.6 million in 2023, largely due to reduced spending on its lead product candidate, cadisegliatin (TTP399). This decrease was offset by an increase in indirect costs, including payroll and bonuses. General and administrative expenses rose to $13.7 million, up from $11.9 million in the prior year, driven by higher payroll costs and share-based compensation. The company continues to invest heavily in its clinical programs, particularly for cadisegliatin, which is being developed as an adjunctive therapy for type 1 diabetes.

In terms of strategic developments, vTv Therapeutics lifted a clinical hold on cadisegliatin imposed by the FDA in July 2024, allowing the company to resume its Phase 3 clinical trial in the second quarter of 2025. The FDA had previously granted Breakthrough Therapy designation for cadisegliatin, which is expected to expedite its development and review process. Additionally, the company is collaborating with G42 Investments to initiate a Phase 2 trial in the Middle East for type 2 diabetes patients, with plans to begin in 2025.

As of December 31, 2024, vTv Therapeutics had cash and cash equivalents of $36.7 million, bolstered by a recent private placement that raised approximately $51.0 million. However, the company acknowledges the need for additional capital to fund ongoing and future clinical trials, raising concerns about its ability to continue as a going concern. The company is exploring various financing strategies, including equity investments and potential licensing agreements, to support its operations and development programs.

Looking ahead, vTv Therapeutics remains focused on advancing cadisegliatin and its other drug candidates through clinical trials while navigating the challenges of funding and regulatory approval. The company’s future performance will depend on its ability to secure additional financing, successfully execute its clinical development plans, and ultimately achieve regulatory approval for its product candidates.